Torax pulls in $30M to market gastro device

The Linx reflux management system uses magnetic beads to augment the esophageal sphincter--courtesy of Torax Medical

Torax Medical completed a $30 million Series D round, money the company will use to further market its line of sphincter-augmentation devices.

Torax's lead device is the Linx reflux management system, a laparoscopic implant designed to treat gastroesophageal reflux disease. Linx got FDA approval in March, and Torax says this $30 million cash infusion will help the company make its case to payers and providers, expanding the device's adoption.

"Billions of dollars are directed annually at reflux disease, but very little of this healthcare investment goes to correcting the underlying defect, which is the esophageal sphincter," Torax CEO Todd Berg said in a statement. "In today's cost-sensitive healthcare environment, patients and payers want more. We believe the [Linx system] will help curb the economic burden of this disease and start to address the growing incidence of serious complications associated with insufficient treatment."

The Linx implant is made up of interlinked titanium beads with magnetic cores, designed to augment the esophageal sphincter's barrier functions and prevent reflux. As the company points out, acid-suppression drugs, like Prevacid, work to slow acid production, but they don't correct the sphincter defects that cause the problem in the first place. This is where Linx stands alone, Torax says.

Piper Jaffray led the $30 million round, supported by Sanderling Ventures; Thomas, McNerney & Partners; Accuitive Medical Ventures; Kaiser Permanente; and Mayo Medical Ventures.

- read Torax's release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.